Trading FDA, Clinical Trial Binary Events at BioRunUp.com: $ISTA $ARNA $VVUS $ISA.TO (IBB, rated BUY)

Posted on June 23, 2010 at 08:18 AM EDT

Below are summaries of the most recent articles written by Mark Messier at www.BioRunUp.com - please visit the site to read the full articles, in addition to many other free tools and strategies related to binary event investing. ISTA - sNDA for XiDay with a PDUFA Date of 10/16/10 ISTA (ISTA Pharmaceuticals) is another company with a drug up for an October FDA Approval. As recently as last month ISTA was trading in the $4 range, and has currently dipped into the mid $2 range. I expect to see $5 - $6 during the run-up to the October 16th PDUFA date. It has a [...] ARNA - Two Upcoming ADA Conference Presentations (With Abstracts) Press Release from ARNA below: SAN DIEGO, June 17, 2010 - /PRNewswire-FirstCall/ - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that new data analyses from lorcaserin's pivotal Phase 3 clinical trial program will be presented in poster sessions at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida. The two posters highlighted below will be displayed in the [...] VVUS - Six Upcoming ADA Conference Presentations (With Abstracts) Vivus (NASDAQ:VVUS) just announced that it has a total of 6 upcoming presentations at the 70th Annual ADA (American Diabetic Association) conference (June 25-29, 2010). These presentations will include reviews of Qnexa's data, and may have an impact on share price. Below you will find text from Vivus' press release with a link to each abstract [...] ISA.TO Run-Up Right on Schedule Today ISA.TO (IPHAF) hit a 52 week hight at $.43, trading at over 8x its average daily volume. On June 3rd I published an article on ISA.TO (see link here) when the price was at $.27, recommending a buy before the run-up began. Today's peak represented a 60% gain in price and we still have [...] Are You Unhappy With BioMedReports.com? Are you unhappy with BioMedReports.com? I know that I am. I have been a paid subscriber since August of 2009. In March of 2010 I requested to have the unused part of annual my membership refunded. This request was quickly rejected with the reply "Unfortunately there are no refunds". To add insult, BioMedReports (BMR) is [...] This Week's Watch List 6/21/10 ISA.TO (IPHAF) - #1 on the Watchlist this week is Isotechnika Pharma. On Monday of next week (June 28th) they have an FDA Advisory Panel for their main drug, Voclosporin. A reminder to those who are new to trading FDA Panel catalysts, the FDA releases the official "notes" to the meeting a few days ahead [...] FDA Calendar Updates 6/18/10 CLDA - PDUFA for drug Vilazodone 1/22/11 PLX - UNCONFIRMED FDA Date for ULYPSO (Orphan Status and Priority Review) 10/27/10 ALKS - FDA Panel for Vivitrol 9/16/10 www.mikehavRx.com is your prescription for stock index investing updates focused on the healthcare sector, medical innovation, and pending binary events such as FDA decisions and clinical trials. The actively managed HavRx Regulatory Catalyst Index update report is currently tracking 599 entries and 396 companies (including approximately 200 stocks trading under $5 per share and 49 private companies). Promo codes (50% discount) are available for college students, investment clubs, and subscribers to my previous FDA Calendar or similar services. Disclosure: No positions